Holen Sie sich die Stockscreener-App
142.69
1.39%
1.96
Schlusskurs vom Vortag:
$140.73
Offen:
$141.75
24-Stunden-Volumen:
333.69K
Relative Volume:
0.66
Marktkapitalisierung:
$7.82B
Einnahmen:
$360.35M
Nettoeinkommen (Verlust:
$-149.57M
KGV:
-53.04
EPS:
-2.69
Netto-Cashflow:
$-81.27M
1W Leistung:
+0.88%
1M Leistung:
+9.27%
6M Leistung:
+31.04%
1J Leistung:
+139.69%
1-Tages-Spanne:
$141.56
$144.51
1-Wochen-Bereich:
$139.54
$146.86
52-Wochen-Spanne:
$59.58
$146.86
Glaukos Corporation Stock (GKOS) Company Profile
Firmenname
Glaukos Corporation
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Vergleichen Sie GKOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
142.69 | 7.82B | 360.35M | -149.57M | -81.27M | -2.69 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corporation Aktie (GKOS) Neueste Nachrichten
Ophthalmic Devices Market Worth 66.71 Bn by 2027 | Hoya Group, Gulden Ophthalmics, FCI Ophthalmics, Glaukos - EIN News
Analyst Scoreboard: 5 Ratings For Glaukos - Inkl
Glaukos price target raised to $149 from $140 at BTIG - TipRanks
Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally? - MSN
Loomis Sayles & Co. L P Grows Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
Intech Investment Management LLC Purchases 9,088 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Eagle Asset Management Inc. Has $11.12 Million Stake in Glaukos Co. (NYSE:GKOS) - MarketBeat
6,080 Shares in Glaukos Co. (NYSE:GKOS) Bought by Jennison Associates LLC - MarketBeat
Glaukos (NYSE:GKOS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Glaukos stock soars to all-time high of $145.97 amid robust growth - Investing.com Australia
When (GKOS) Moves Investors should Listen - Stock Traders Daily
Connor Clark & Lunn Investment Management Ltd. Has $6.11 Million Holdings in Glaukos Co. (NYSE:GKOS) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Buys New Shares in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos stock soars to all-time high of $145.97 amid robust growth By Investing.com - Investing.com South Africa
Primecap Management Co. CA Increases Stock Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
Segall Bryant & Hamill LLC Sells 4,327 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Co. (NYSE:GKOS) is Brown Capital Management LLC's 4th Largest Position - MarketBeat
Glaukos (FRA:6GJ) Cyclically Adjusted FCF per Share : €-0.43 (As of Sep. 2024) - GuruFocus.com
Glaukos Co. (NYSE:GKOS) Shares Bought by Victory Capital Management Inc. - MarketBeat
Glaukos Corp (GKOS) Trading 4.94% Higher on Nov 19 - GuruFocus.com
First Turn Management LLC Takes Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
LMR Partners LLP Grows Holdings in Glaukos Co. (NYSE:GKOS) - MarketBeat
Oppenheimer Asset Management Inc. Sells 3,974 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Here's Why You Should Retain Glaukos (GKOS) Stock for Now - MSN
Glaukos Revolutionizes Glaucoma Treatment with iDose TR Approval - TipRanks
Brown Capital Management LLC's Strategic Reduction in Glaukos Co - GuruFocus.com
(GKOS) Long Term Investment Analysis - Stock Traders Daily
Glaukos Co. (NYSE:GKOS) Shares Bought by WCM Investment Management LLC - MarketBeat
Principal Financial Group Inc. Sells 9,441 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Lisanti Capital Growth LLC Sells 20,320 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates - MSN
Glaukos Announces Participation in Upcoming Investor Conferences - BioSpace
William Blair Comments on Glaukos' Q4 Earnings (NYSE:GKOS) - MarketBeat
Glaukos to Present at 5 Major Healthcare Investor Conferences in Q4 2024 | GKOS Stock News - StockTitan
Glaukos Corporation (NYSE:GKOS) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Glaukos stock soars to all-time high of $139.53 amid robust growth - Investing.com
Glaukos Corporation (NYSE:GKOS) Q3 2024 Earnings Call Transcript - MSN
Glaukos price target raised to $145 from $135 at Wells Fargo - Yahoo Finance
Glaukos Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Glaukos price target raised to $140 from $139 at BTIG - TipRanks
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market | Futu - WICZ
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - MSN
Glaukos (NYSE:GKOS) Shares Gap DownHere's What Happened - MarketBeat
Glaukos (NYSE:GKOS) Releases Earnings Results, Beats Estimates By $0.20 EPS - MarketBeat
Earnings call: Glaukos reports strong Q3 growth, raises 2024 guidance - Investing.com
Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
JPMorgan Chase & Co. Issues Positive Forecast for Glaukos (NYSE:GKOS) Stock Price - MarketBeat
Piper Sandler reaffirms stock target on Glaukos post-Q3 beat - Investing.com
BTIG reiterates Buy on Glaukos stock as strong iDose sales support growth outlook - Investing.com
Glaukos Co. (NYSE:GKOS) Receives $130.45 Average PT from Analysts - MarketBeat
Glaukos Corp (GKOS) Q3 2024 Earnings Call Highlights: Record Sal - GuruFocus.com
Finanzdaten der Glaukos Corporation-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):